secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2026-05-27T20:01:33+00:00
Accession:  0001447028-26-000024
Event type: other
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus shareholders approve 2026 omnibus equity plan authorizing 16.3M shares
------------------------------------------------------------------------------

- Shareholders elected all five director nominees: Androski, Beardsley, Bishop, Gline, Sawhney.
- 2026 Omnibus Share and Incentive Plan approved (138.9M for, 7.4M against); replaces 2011 and 2016 plans.
- Plan authorizes 16,300,000 common shares for issuance as options, SARs, restricted shares, etc.
- Non-binding advisory vote on executive compensation passed (137.6M for, 8.3M against).
- Ernst & Young LLP ratified as independent auditor for FY 2026 (164.4M for, 2.1M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000144702826000024/0001447028-26-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000144702826000024/abus-20260526.htm
  HTML page:      https://secwatch.observer/filing/0001447028-26-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer